Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis

Table 1 Characteristics of included studies

Author	Year	Country	Study design	Clinical setting	Endpoint	Sample size (n)	Male (%)	Age	CURB65 % (2–5)	PSI % (IV–V)	Prevalence of mortality (%)	Cut-off (nmol/L)	TP	FP	FN	TN	Sen (95 % CI)	Spe (95 % CI)
Albrich [27]	2011	Switzerland	MRCT + CR	ED	30 day mortality	925	-	-	53.8	NA	5.41	1.5	36	295	14	580	72	66.3
					Adverse events						14.5	0.75	256	475	11	183	95.9	27.8
Bello [28]	2012	Spain	PR + CR	ED	30 day mortality	224	61	73 (63–80)	59.2	61	5.8	1.066	12	68	1	143	92.3	67.46
					Complications						64	0.833	98	26	48	52	67.35	66.23
Christ-Crain [29]	2006	Switzerland	PR + CR	ED	6.9 ± 1.9 weeks	302	61.9	69.6 ± 17.0	-	60.2	12.6	1.8	30	74	8	190	80	72
Courtais [30]	2013	France	PR + CR	ED	30 day mortality	109	65.1	71.1 (53–84)	-	56	8.26	1.8	7	25	2	75	77.8	75
Huang [31]	2009	America	MPR	ED	30 day mortality	1653	52	65.0 ± 18.5	-	39	6.4	1.3	72	418	34	1129	68	73
Kolditz [32]	2012	Germany	PR + CR	ED	ICU admission or 7 day mortality	51	49	72 (41–80)	-	-	17.6	1.05	6	6	3	36	67	85
Kruger [33]	2009	Germany	RCT + CR	ED	28 day mortality	728	59.1	59 ± 18.2	-	-	2.5	0.959	14	168	4	542	77.8	76.3
Julian-Jimenez [34]	2014	Spain	PR + CR	ED	30 day mortality	127	74	65.8 ± 20.02	55.9	55.1	10.3	1.85	11	21	2	93	84.6	81.4
Suberviola [35]	2012	Spain	PR	ICU	In-hospital mortality	49	67.3	59.4 ± 13.4	-	-	35	4.86	9	5	8	27	53	84
Lacoma [36]	2014	Spain	PR	HW	Complications	85	69.4	-	48.2	61.2	10.6	1.5	6	26	3	50	66.7	65.8
Bereciartua Urbieta [37]	2011	Spain	PR	ED	Unfavorable outcome	250	31.6	71.1	-	-	33.2	1.2	66	78	17	89	80	53
Renaud [38]	2012	America/Spain/France	MRCT + CR	ICU	SCAP	877	58.8	73 (59–83)	-	-	5.6	1.8	49	184	31	613	61.3	76.9

SCAP severe community-acquired pneumonia, ICU intensive care unit, ED emergency department, HW hospital ward, PR prospective recruitment, CR consecutive recruitment, RR retrospective recruitment, RCT randomized controlled trial, MPR multi-center prospective recruitment, MRCT multi-center random controlled trial, TP true positive, FP false positive, TN true negative, FN false negative, SEN sensitivity, SPE specificity, CI confidence interval

ISSN: 1471-2334